High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer.
High-dose chemotherapy as adjuvant treatment for high-risk breast cancer has been and is being investigated in a series of randomized trials. The preliminary information from 5 studies is difficult to interpret. The data are consistent with a modest benefit of high-dose therapy, but strong evidence for this is lacking. Additional follow-up and the results of several large trials outside the United States are awaited. Hitherto unrecognized pharmacologic interactions between high-dose agents and long-term toxicities such as cognitive function impairment complicate the issue considerably.
Rodenhuis
S
S
Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam.
Huitema
A D
AD
van Dam
F S
FS
de Vries
E G
EG
Beijnen
J H
JH
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003071:Cognition / Q000187:drug effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D013852:Thiotepa / Q000008:administration & dosage / Q000627:therapeutic use
D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; D013852:Thiotepa